Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market
This article was originally published in The Pink Sheet Daily
Vernalis reveals new strategy to market long-acting prescription cough/cold preparations in the US, supported by Tris Pharma's technology and a $104 million fundraising
You may also be interested in...
Disappointing sales growth of its prescription extended-release cough-and-cold product has led Vernalis to decide to close down its US commercial operations, and to seek a buyer for the whole company.
Vernalis launches its first long-acting liquid cough and cold product, Tuzistra XR, in the US as part of a revised business focus on generating sustainable revenues from low development risk, late-stage products.
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis